Main Menu

Loxo Oncology, Inc.

(NASDAQ GM: LOXO)

Summary

Attention investors who purchased shares of Loxo Oncology, Inc. before January 7, 2019:

Rigrodsky & Long is investigating potential claims against the board of directors of Loxo Oncology, Inc. concerning possible breaches of fiduciary duty and other violations of law related to the Company’s agreement to be acquired by Eli Lilly and Company for $235.00 per share, or approximately $8.0 billion.

Press Release

Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of Loxo Oncology, Inc. (“Loxo Oncology” or the “Company”) (NASDAQ GM: LOXO) regarding possible breaches of fiduciary duties and other violations of law related to the Company’s entry into an agreement to be acquired by Eli Lilly and Company (“Eli Lilly”) (NYSE: LLY) in a transaction valued at approximately $8.0 billion.  Under the terms of the agreement, shareholders of Loxo Oncology will receive $235.00 in cash for each share of Loxo Oncology common stock.

If you own common stock of Loxo Oncolgy and purchased any shares before January 7, 2019, if you would like to learn more about this investigation, or if you have any questions concerning this announcement or your rights or interests, please contact Seth D. Rigrodsky or Gina M. Serra toll-free at (888) 969-4242, by e-mail at info@rl-legal.com, or at https://www.rigrodskylong.com/offices-contact.  

Rigrodsky & Long, P.A., with offices in Delaware, New York, and California, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in numerous cases nationwide, including federal securities fraud actions, shareholder class actions, and shareholder derivative actions.

Attorney advertising.  Prior results do not guarantee a similar outcome.

Back to Page